Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;132(2):490-5.
doi: 10.1016/j.ygyno.2013.11.030. Epub 2013 Dec 3.

Ovarian cancer screening--current status, future directions

Usha Menon  1 , Michelle Griffin  2 , Aleksandra Gentry-Maharaj  3
Affiliations
Review

Ovarian cancer screening--current status, future directions

Usha Menon et al. Gynecol Oncol. 2014 Feb.

Abstract

Evidence of a mortality benefit continues to elude ovarian cancer (OC) screening. Data from the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial which used a screening strategy incorporating CA125 cut-off and transvaginal ultrasound has not shown mortality benefit. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is using the Risk of Ovarian Cancer (ROC) time series algorithm to interpret CA125, which has shown an encouraging sensitivity and specificity however the mortality data will only be available in 2015. The article explores the impact of growing insights into disease aetiology and evolution and biomarker discovery on future screening strategies. A better understanding of the target lesion, improved design of biomarker discovery studies, a focus on detecting low volume disease using cancer specific markers, novel biospecimens such as cervical cytology and targeted imaging and use of time series algorithms for interpreting markers profile suggests that a new era in screening is underway.

Keywords: Biomarkers; Imaging; Ovarian cancer; Screening; UKCTOCS.

PubMed Disclaimer

References

    1. Castle P.E. Gynecological cancer: more evidence supporting human papillomavirus testing. Nat Rev Clin Oncol. 2012;9:131–132. - PubMed
    1. Moyer V.A., Force USPST Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157:900–904. - PubMed
    1. Buys S.S., Partridge E., Greene M.H. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193:1630–1639. - PubMed
    1. Buys S.S., Partridge E., Black A. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295–2303. - PubMed
    1. Pinsky P.F., Miller A., Kramer B.S. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol. 2007;165:874–881. - PubMed

MeSH terms